Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 25;2(5):e000338. doi: 10.1161/JAHA.113.000338

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 6. — Comparison of scar size reduction in (A) SCIPIO, (B) CADUCEUS, and (C) POSEIDON trials. A, SCIPIO Trial 1‐year follow‐up shows infarct size reduction at 4 and 12 months after CSC therapy. B, CADUCEUS trial showed decreases in scar mass and increases in viable mass on MRI in patients treated with CDCs but not controls. C, Myocardial infarct (MI) size reduction shown in POSEIDON trial. Panel A reproduced with permission from Chugh et al, Circulation, 2012⁴; panel B from Makkar et al, Lancet, 2012⁵; and panel C from Hare et al, JAMA, 2012.¹ CADUCEUS indicates Cardiosphere‐Derived aUtologous stem Cells to reverse ventricUlar dySfunction; CDC, cardiosphere‐derived cell; CSCs, cardiac stem cells; EED, early enhancement defect; MRI, magnetic resonance imaging; MSCs, mesenchymal stem cells; POSEIDON, PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis; SCIPIO, Stem Cell Infusion in Patients with Ischemic cardiomyopathy.